Client Presentation & Sign-off
Transform Maverick Bio's web presence with an iktos.ai-inspired design that showcases dual-use biotech innovation through sophisticated 3D molecular animations and dark-themed visual storytelling.
2 weeks build + 3 days Webflow
$3,000 (50% down / 50% delivery)
Inspired by iktos.ai's sophisticated dark theme with strategic purple accents
Primary background, highest contrast
Secondary backgrounds, cards
Primary accent, sophisticated & professional
Secondary accent, animations, hover states
Primary text, maximum contrast
text-4xl font-bold
text-2xl font-semibold
Body text for detailed descriptions and content sections. Optimized for readability against dark backgrounds.
text-base text-gray-300
Caption and metadata text
text-sm text-gray-400
Subtle gradients with purple borders for depth
Muted backgrounds for supporting content
Backdrop blur for layered interfaces
iktos.ai-inspired centered hero with prominent molecular animation and multi-colored headlines
Maverick Bio leverages cutting-edge AI and robotics in drug discovery. By integrating the precision of synthetic biology with automated synthesis and testing, we are forging a path towards dual-use therapeutics, accelerating the development of field-ready biotechnologies to improve warfighter care and unlock massive civilian markets.
iktos.ai-inspired layout with centered content for maximum visual impact
Purple "Therapeutics", Green "Defense", Blue "Innovation" for brand association
Prominent iktos.ai Makya video with purple brand filter and glow effects
64px headlines, 17px body text, and spacious layout matching iktos.ai
iktos.ai sticky video pattern with scroll-based video switching
DUAL-USE INNOVATION
At Maverick Bio, we develop precision therapeutics at the intersection of synthetic biology and national defense. As AI reshapes drug discovery, we're redefining drug utility—building dual-use therapies that solve high-stakes challenges for warfighters and unlock massive civilian markets.
Key Features
STRATEGIC POSITIONING
We operate at the convergence of defense, biotech, and health security—a space where global demand is rising and traditional pharma hasn't yet caught up. Our synthesis planning approach ensures rapid deployment capabilities.
Market Advantages
THERAPEUTIC PIPELINE
Our pipeline spans gene therapies that regenerate muscle in days, antibody-based countermeasures to fentanyl-class chemical threats, and orally delivered metabolic peptides—all field-deployable, scalable, and protected by strong IP. Our automated systems ensure consistent quality and rapid production.
Pipeline Highlights
Right video changes automatically as user scrolls through left content sections
Tracks section visibility with optimized trigger zones for smooth transitions
Company → Makya, Market → Spaya, Pipeline → Robotics videos from iktos.ai
Section indicators and titles update to show active content area
iktos.ai inspired expandable cards with detailed information and stage tracking
Explore our pipeline showcasing the breadth and depth of our ongoing projects.
IGF-1 plays a key role in muscle hypertrophy, repair, and vascularization. Our AAV9-based therapy delivers IGF-1 selectively to skeletal muscle via systemic injection—activating local growth without elevating systemic hormone levels.
In early human testing, visible hypertrophy occurred within 7 days, with no heart or liver uptake and minimal side effects. MVR-101, our lead candidate, is a muscle-specific AAV9-IGF1 construct with a clean safety profile, field-ready dosing format, and rapid therapeutic onset.
Timeline: Preclinical-to-clinical transition planned for 2025, with DoD partnership providing non-dilutive funding pathway.
Fentanyl and its analogs are among the most potent synthetic opioids ever developed, posing both public health and battlefield chemical threats. Our long-acting antibody neutralizes fentanyl molecules in the bloodstream before they can bind to CNS receptors.
It has demonstrated protection against carfentanil at 10x lethal dose equivalents in vivo, while maintaining full compatibility with naloxone for emergency reversal. MVR-201 is engineered for ultrahigh affinity (Kd ~70 pM) and 95–98% fentanyl capture post-exposure.
Timeline: Preclinical studies ongoing; IND-enabling studies projected for late 2025.
Peptide YY₃₋₃₆ acts on the Y2 receptor to signal satiety, but suffers from poor stability and off-target effects. Our novel PYY analog is optimized for buccal (oral mucosal) delivery, engineered from canonical amino acids for Y2 selectivity.
It avoids immunogenicity and can be produced in GRAS-certified microbial hosts. MVR-301, 302, 305 show superior Y2R binding, enhanced half-life under physiological conditions, and minimal off-target activity at Y1/Y5 receptors.
Timeline: In-silico candidate screening complete; in vitro validation underway with field deployment optimization.
Click to expand for detailed information - exact iktos.ai interaction pattern
Multi-color progress bars with stage labels showing development progression
Full therapeutic descriptions, mechanisms, and timelines in expandable sections
Smooth animations and hover states enhance user experience
From Maverick Metals' clean tech aesthetic to Maverick Bio's sophisticated biotech presence
Clean, minimalist design with high contrast. Focus on technical innovation and Y Combinator credibility.
Sophisticated dark theme with molecular animations. Premium biotech aesthetic targeting both defense and pharmaceutical markets.
From clean minimalism to sophisticated 3D molecular animations that demonstrate scientific expertise
Expanding from industrial buyers to dual DoD/pharmaceutical decision makers requiring premium presentation
Evolution from startup-focused to enterprise-ready, matching the sophistication of biotech industry leaders
Technical details for integrating your GLB model into the hero section
import { useGLTF } from '@react-three/drei'import { Canvas } from '@react-three/fiber'function DNAModel() {const gltf = useGLTF('/models/dna.glb')return (<primitiveobject={gltf.scene}scale={[1.5, 1.5, 1.5]}rotation={[0, rotation, 0]}/>)}
Your GLB model is ready for integration. During development, we'll move the file to the /public/models/ directory and implement the Three.js canvas with smooth rotation animation and optimized lighting.
Review and approve this design direction
• Stakeholder review
• Feedback incorporation
• Final sign-off
Begin 2-week development sprint
• Asset preparation
• Component development
• Testing & optimization
Transfer to CMS for team management
• CMS setup
• Content migration
• Team training
50% down payment • 50% on delivery
We're excited to bring this vision to life for Maverick Bio. Questions about the proposal or ready to get started?